Current Appointments & Affiliations
Eleanor Easley Distinguished Professor in the School of Medicine
·
2023 - Present
Medicine, Medical Oncology,
Medicine
Professor of Medicine
·
2015 - Present
Medicine, Medical Oncology,
Medicine
Professor in Surgery
·
2015 - Present
Surgery,
Clinical Science Departments
Professor in Urology
·
2025 - Present
Urology,
Clinical Science Departments
Member of the Duke Cancer Institute
·
2003 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Figure S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer
Other · November 25, 2025 <p>Percent PSMA expression positivity (PSMA+CTC x 100/ Traditional CTC) across PSMA+ Neuroendocrine Phenotype (NE) - and PSMA+ NE+ baseline (A) and progression (B) samples.</p> ... Full text CiteFigure S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer
Other · November 25, 2025 <p>Kaplan Meier plots depict the association between PSMA+ CTC enumeration and OS and PFS. The associations of PSMA+ CTC enumeration with overall survival (OS) and progression-free survival (PFS) were explored using the proportional hazard mo ... Full text CiteFigure S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer
Other · November 25, 2025 <p>Waterfall plots depicting A) the proportion of men achieving a 50% or greater PSA decline from baseline, confirmed with a subsequent value (confirmed PSA50) and B) best overall objective radiographic responses among response evaluable subj ... Full text CiteRecent Grants
Lutetium Long-term Safety Follow-up study
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2023 - 2035A Phase 2, Open-label Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants with PSMA PET-Positive Castration-Resistant Prostate Cancer
Clinical TrialPrincipal Investigator · Awarded by Convergent Therapeutics, Inc. · 2025 - 2030ACS Professor Award - Race based cohort trials to improve outcomes for Black men
Public ServicePrincipal Investigator · Awarded by American Cancer Society, Inc. · 2024 - 2029View All Grants
Education, Training & Certifications
Duke University ·
1992
M.D.